

**REMARKS**

Claims 2-4, 6-8, 10-12, 14-16, 18-20, 22-24, 26-28, 30-32, 34-36, 38-40, 42-44, 46-48, 50-54, and 56-65 are withdrawn as being directed to non-elected subject matter. Claims 5, 9, 13, 17, 21, 25, 29, 33, 37, and 41 are withdrawn as being directed to non-elected amino acid of SEQ ID Nos: 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22, respectively. Claim 49 has been cancelled without prejudice or disclaimer. Claim 1 has been amended to recite an isolated protein comprising “the amino acid sequence of SEQ ID NO: 2 or a salt thereof.” Support for the amendment can be found in the specification, for example, at least at p. 17, lines 27-29. Claim 45 has been amended to correct the case of the word “claim” and to recite a “composition for modulating the differentiation of and/or metabolism in an adipocyte comprising the protein or a salt thereof.” Support for the amendment can be found, for example, at least at the paragraph bridging p. 70 and p. 71 and at Example 4 at p. 149, line 6 to p. 150, line 7. Claim 55 has been amended to correct the case of the word “claim” and to delete the language “its partial peptide.” Claims 66-67 have been added. Support for claim 66 can be found throughout the specification, for example, at least at the paragraph bridging p. 70 and p. 71 and at Example 4 at p. 149, line 6 to p. 150, line 7. Support for claim 67 can be found throughout the specification, for example, at least at p. 59, line 4 to p. 63, line 1, p. 69, line 33 to p. 71, line 4, and at Example 4 at p. 149, line 6 to p. 150, line 7. Thus, the amended and new claims are fully supported by the specification and contain no new matter.

Applicants respectfully request entry of the amendments. Once entered, claims under consideration are claims 1, 45, 55, and 66-67.

## **IDS**

Applicants note with appreciation that “the references cited in the IDS filed 8/9/05, the IDS filed 1/10/05 and the IDS filed 6/5/07 have been considered by the Examiner.” Office Action at p. 2. Applicants note that references WO 01/57188, WO 01/00638, WO 01/64835, and WO 01/48192 in the IDS filed August 9, 2005, have not been initialed. Applicants respectfully request consideration of those references and that the Office initial those references after they have been considered.

## **Objections to the Specification**

The Office has objected to the disclosure.

First, the Office has required that the continuing data of this application should be updated. Accordingly, Applicants have amended the specification to include the priority data.

Second, the Office has required that Applicants “delete the embedded hyperlink and/or other forms of browser executable code.” Office Action at p. 3. According to the Office, “Applicants may remove “http://” so that the hyperlinker becomes inactive, i.e., the content followed by Http:// can be and should be left behind; and thus, a browser will only interpret the rest of the URL as text.” *Id.* Accordingly, Applicants have amended the specification to remove the term “http://.”

Third, the Office has required that

at page 34, line 9, “RACE” should be spelled out in full for the first instance of use; see also page 59, line 19-21, “PACAP”, “GHRH”, “CRF”, “ATCH” “GRP”, “PTH”; page 59, lines 25-26, “GRO”, “NAP”, “ENA”, “PF4” “IP10”, “GCP”, “MCP”, “HC14”, “MIP” and “RANTES”.

Office Action at p. 3.

Each of these acronyms are disclosed in the specification and their full names are well-known in the art. Nonetheless, Applicants have amended the specification to spell out each name. For example, in the second full paragraph at p. 34, the specification discloses “RACE,” which is known in the art as “rapid amplification of cDNA ends.” See p. 8998, left column of Frohman et al. (*Proceedings of the National Academy of Sciences USA* 85:8998-9002, 1988) (copy enclosed).

At the paragraph bridging pages 59 and 60, the specification discloses “PACAP,” “GHRH,” “CRF,” “ACTH,” “GRP,” “PTH,” “TRH,” “GRO,” “NAP,” “ENA,” “PF4,” “IP10,” “GCP,” “MCP,” “MIP,” “RANTES,” and “IL.” “PACAP” and “GHRH” are known in the art as “pituitary adenylate cyclase-activating polypeptide” and “growth hormone-releasing hormone,” respectively. See Abstract of Montero et al. (*Journal of Molecular Endocrinology* 25:157-168, 2000) (copy enclosed). “CRF” and “ACTH” are known in the art as “corticotropin-releasing factor” and “adrenocorticotropin hormone.” See Abstract and p. 212, right column, second full paragraph in Sarnyai et al. (*Pharmacological Reviews* 53(2):209-243, 2001) (copy enclosed). “GRP” is known in the art as “gastrin-releasing peptide.” See Abstract of Wada et al. (*The Journal of Neuroscience* 10(9):2917-2930, 1990) (copy enclosed). “PTH” is known in the art as “parathyroid hormone.” See Abstract of Mannstadt et al. (*American Journal of Physiology-Renal Physiology* 277:665-675, 1999) (copy enclosed). “TRH” is known in the art as “thyrotropin-releasing hormone.” See Summary of Bílek (*Physiological Research* 49 (Suppl.1):S19-S26, 2000) (copy enclosed). “GRO,” “NAP,” “ENA,” “PF4,” “IP10,” “GCP,” “MCP,” “MIP,” “RANTES,” and “IL” are known in the art as “growth-related oncogene,” “neutrophil-activating protein,” “epithelial cell-derived neutrophil-activating factor,” “platelet factor 4,” “interferon-inducible protein 10,” “granulocyte chemoattractant protein,” “monocyte

chemoattractant protein,” “macrophage inflammatory protein,” “regulated on activation normal T cell expressed and secreted,” and “interleukin.” See Table 1 at p. 148 in Murphy et al.

(*Pharmacological Reviews* 52 (1):145-176, 2000) (copy enclosed).

In the case of “HC14,” Applicants note that “[d]ifferential library screening with cDNA probes derived from stimulated versus resting PBL led to identification of two novel sequences, termed HC11 and HC14.” Abstract of Chang et al. (*International Immunology* 1(4):388-397, 1989) (copy enclosed). Thus, according to Chang et al., the factor “HC14” is a term known in the art. Therefore, Applicants have not spelled out HC14 in the specification.

Because one skilled in the art would understand what these acronyms represent, no new matter has been added. Withdrawal of the objection is respectfully requested.

**Amendment to Correct a Typographical Error in the Specification**

Applicants have amended the paragraph bridging page 16 and page 17 to correct a typographical error in the word “Edman.” Thus, no new matter has been added.

**Rejections Under 35 U.S.C. § 112, Second Paragraph**

Claims 1, 45, 49, and 55 are rejected under 35 U.S.C. § 112, second paragraph, as allegedly “being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.” Office Action at p. 3.

First, the Office states that “[c]laim 1 recites ‘substantially the same as the amino acid sequence...’; the recitation is unclear in the metes and bounds of the relationship between the claimed protein and SEQ ID NO:2 in terms of the claim language ‘substantially the same as...’”

Office Action at p. 4. Second, the Office states that claim 1 is “indefinite in the recitation of ‘represented by.’...Claims 45, 49, and 55, which depend from claim 1, are also rejected.” *Id.*

Applicants respectfully traverse. Amended claim 1 recites “an isolated protein comprising the amino acid sequence of SEQ ID NO:2 or a salt thereof.” Therefore, withdrawal of the rejection is respectfully requested.

**Rejections Under 35 U.S.C. § 112, First Paragraph**

**Written description**

The Office has rejected claims 1, 45, 49, and 55 under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the written description requirement. According to the Office, “the specification contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.” Office Action at p. 5.

The Office states that “[c]laim 1 is directed to a genus of isolated proteins comprising a polypeptide which is substantially the same as the amino acid sequence or a partial sequence thereof.” Office Action at p. 5.

The Office further states that:

[t]he specification neither provides representative species to describe the ‘partial sequence’ or the sequence which is substantially homologue to the instant SEQ ID NO:2...nor provides animal model for the disclosed pharmaceutical composition (claims 45 and 49) comprising (i) the polypeptide of SEQ ID No:2 or (ii) the ‘partial peptide’ or (iii) the variant sequence substantially homologue to SEQ ID NO:2 wherein (i), (ii), or (iii) is used as a prophylactic (preventative) and/or therapeutic agent for disease involving abnormal adipocytes differentiation (claim 49). Both the art in related field and the instant disclosure fail to teach this regard. Therefore, applicants are not in possession of the claimed amino acid sequence

comprising variant polypeptide or oligopeptide which is the partial sequence of the full-length SEQ ID NO:2 (claim 1), the pharmaceutical composition (claims 45 and 49) and the kit (claim 55) comprising the sequence thereof.

Office Action at p. 7.

Applicants respectfully traverse. Amended claim 1 recites “an isolated protein comprising the amino acid sequence of SEQ ID NO:2 or a salt thereof.”

Amended claim 45 recites “a composition for modulating the differentiation of and/or metabolism in an adipocyte comprising the protein or a salt thereof according to claim 1, and a pharmaceutically acceptable carrier, recipient or diluent.”

Claim 49 has been cancelled without prejudice or disclaimer. Moreover, amended claim 55 no longer recites “its partial peptide.”

Therefore, withdrawal of the rejection is respectfully requested.

#### Enablement

Claims 1, 45, 49, and 55 are also rejected under 35 U.S.C. 112, first paragraph allegedly because “the specification while being enabling for the isolated protein of SEQ ID NO:2 and a composition thereof, does not reasonably provide enablement for all proteins encompassed by the claims and the pharmaceutical composition and kits thereof. The specification does not enable any person skilled in the art to which it pertains, or with which it is most clearly connected, to make and use the invention commensurate in scope with these claims.” Office Action at p. 8.

The Office states that:

claims are directed to the isolated variant polypeptide/peptide which is substantially the same as the amino acid sequence or partial sequence (claim 1)...The specification does not teach that the variant polypeptide or oligopeptide has the activity of the full-

length sequence of SEQ ID NO: 2, nor provides working examples thereof, and the claims do not require that the claimed protein have any particular function or activity. Also the specification fails to provide the working example or animal model for the claimed pharmaceutical composition comprising the polypeptide of SEQ ID NO:2 or the variant molecule thereof, and for the kit comprising the variant molecule thereof; where the scope of pharmaceutical composition is so broad as to prevent (prophylactic) or treat any disease involving abnormality of adipocytes differentiation and/or metabolism function.

Office Action at p. 9.

Applicants respectfully traverse.

Amended claim 1 recites “an isolated protein comprising the amino acid sequence of SEQ ID NO:2 or a salt thereof.”

Amended claim 45 recites “a composition for modulating the differentiation of and/or metabolism in an adipocyte comprising the protein or a salt thereof according to claim 1, and a pharmaceutically acceptable carrier, recipient or diluent.”

Claim 49 has been cancelled without prejudice or disclaimer. Moreover, amended claim 55 no longer recites “its partial peptide.”

Therefore, withdrawal of the rejection is respectfully requested.

**Rejections Under 35 U.S.C. § 102**

**102(b)**

Claim 1 has been rejected under 35 U.S.C. 102(b) as allegedly being anticipated by Wood et al. (WO 9914328). The Office states that “[i]n patent claim 12, Wood et al. teach an isolated polypeptide comprising SEQ ID NO:310...which has 90.4% sequence identity to instant SEQ ID NO:2..., which anticipate instant claim 1.” Office Action p. 12.

Applicants respectfully traverse.

Amended claim 1 recites “an isolated protein comprising the amino acid sequence of SEQ ID NO:2 or a salt thereof.” Wood et al. does not teach an isolated protein comprising the amino acid of SEQ ID NO:2 or a salt thereof. Thus, withdrawal of the rejection is respectfully requested.

102(e)

Claims 1, 45, 48, and 55 are rejected under 35 U.S.C. 102(e) as allegedly being anticipated by Goddard et al. (U.S. Patent No. 7,189,807). The Office states that

Goddard et al. teach the isolated polypeptide comprising SEQ ID NO:370...which has 90.4% sequence identity to instant SEQ ID NO:2. The polypeptide is isolated because SEQ ID NO:370 is encoded by isolated cDNA clone...because Goddard et al. teach the polypeptide is recombinantly isolated. Thus, Goddard et al. teach the instant claim 1.

Goddard et al. teach a pharmaceutical composition comprising PRO polypeptide (col. 6, lines 14-19) which is encoded by PR0332 cDNA, i.e., PR0332 polypeptide, which consists of SEQ ID NO:332 (Figure 370, col. 24, lines 1-3). The Goddard et al. teachings anticipate instant claim 45.

Since the recitation of claim 49 "which is a prophylactic and/or therapeutic agent for disease ..." is considered to be an intended use which has little patentable weight, the above Goddard et al. teachings anticipate instant claim 49.

Claim 55, reciting a kit, as written, contains no positive recitation of the ingredients which distinguishes it over the references; therefore, the kit (a composition) is encompassed by the Goddard reference.

Office Action at p. 12-13.

Applicants respectfully traverse.



Amended claim 1 recites “an isolated protein comprising the amino acid sequence of SEQ ID NO:2 or a salt thereof,” and claims 45 and 55 depend on claim 1. Moreover, claim 55 no longer recites “its partial peptide,” and claim 49 has been cancelled. Goddard et al. does not teach an isolated protein comprising the amino acid of SEQ ID NO:2 or a salt thereof. Therefore, Goddard et al. does not anticipate the claims. Withdrawal of the request is respectfully requested.

**Rejections Under 35 U.S.C. § 103(a)**

The Office states that “[c]laims 1 and 55 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wood et al. (WO 9914328) in view of Ali et al. (US 20020037540 A1). The rejection of claim 1 by Wood et al. has been discussed above. Yet, Wood et al. do not expressly teach a kit comprising the polypeptide. At [0150], Ali et al. teach a kit comprising a polypeptide useful for identifying ligand, agonist or antagonist for said polypeptide, as applied to claim 55.” Office Action at p. 14.

The Office continues by stating:

It would have been obvious to one of ordinary skill in the art at the time the invention was made to formulate the kit comprising the full-length polypeptide of instant SEQ ID NO:370. This is because the polypeptide of SEQ ID NO:370 (also called: PR0332 polypeptide, see page 107, line 27) taught by Wood et al. is useful for identifying its ligand, e.g., receptor-ligand interaction (see page 98, lines 28-36), and because Ali et al. have taught that the kit developed is useful for the same purpose, i.e., identifying the ligand for said polypeptide. Moreover, it is a well known convention in the art to place these components in a pack or kit for convenience and economy. Therefore, in order to conveniently screening for the ligand including agonist, antagonist or/and receptor of said polypeptide, one skilled in the art would have constructed the kit comprising the polypeptide according to the above references' teachings with reasonable expectation of success.

Therefore, the claimed invention was *prima facie* obvious to make and use the invention at the time it was made.

Office Action at p. 14-15.

Applicants respectfully disagree. Amended claim 1 recites “an isolated protein comprising the amino acid sequence of SEQ ID NO:2 or a salt thereof,” and claim 55, which depends on claim 1, no longer recites “its partial peptide.” As discussed above, Wood et al. does not teach or suggest an isolated protein comprising the amino acid sequence of SEQ ID NO:2 or a salt thereof. Ali et al. does not make up for the deficiencies of Wood et al. Therefore, Wood et al. in view of Ali et al. do not render obvious claims 1 and 55. Withdrawal of the rejection is respectfully requested.

In view of the foregoing amendments and remarks, Applicants respectfully request reconsideration and reexamination of this application and the timely allowance of the pending claims.


Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: January 16, 2008

By: \_\_\_\_\_

  
Yuko Soneoka  
Reg. No. 60,018  
(650) 849-6679

## Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer

(polymerase chain reaction/5' and 3' cDNA ends/cDNA cloning/low-abundance mRNAs/*int-2* gene)

MICHAEL A. FROHMAN, MICHAEL K. DUSH, AND GAIL R. MARTIN

Department of Anatomy, University of California, San Francisco, CA 94143

Communicated by Peter H. Duesberg, September 9, 1988

**ABSTRACT** We have devised a simple and efficient cDNA cloning strategy that overcomes many of the difficulties encountered in obtaining full-length cDNA clones of low-abundance mRNAs. In essence, cDNAs are generated by using the DNA polymerase chain reaction technique to amplify copies of the region between a single point in the transcript and the 3' or 5' end. The minimum information required for this amplification is a single short stretch of sequence within the mRNA to be cloned. Since the cDNAs can be produced in one day, examined by Southern blotting the next, and readily cloned, large numbers of full-length cDNA clones of rare transcripts can be rapidly produced. Moreover, separation of amplified cDNAs by gel electrophoresis allows precise selection by size prior to cloning and thus facilitates the isolation of cDNAs representing variant mRNAs, such as those produced by alternative splicing or by the use of alternative promoters. The efficacy of this method was demonstrated by isolating cDNA clones of mRNA from *int-2*, a mouse gene that expresses four different transcripts at low abundance, the longest of which is ~2.9 kilobases. After <0.05% of the cDNAs produced had been screened, 29 independent *int-2* clones were isolated. Sequence analysis demonstrated that the 3' and 5' ends of all four *int-2* mRNAs were accurately represented by these clones.

Despite the development of numerous cDNA cloning strategies (1–5), obtaining full-length cDNA copies of low-abundance mRNAs remains a formidable task. We describe here a simple, rapid, and efficient cDNA cloning strategy that is based on the DNA polymerase chain reaction (PCR) technique developed by Saiki *et al.* (6). PCR employs two oligonucleotide primers, one complementary to a sequence on the (+) strand and the other to a downstream sequence on the (–) strand. Repetitive cycles of denaturation, annealing, and extension are used to generate multiple copies of the DNA that lies between the two primers. PCR has been used for a variety of purposes (7–13), including the detection of allelic polymorphisms and of DNA sequences unique to rare cells in a population, as well as the cross-species isolation of homologous genes. The feature common to all applications of PCR to date has been the use of primers designed to match two known or presumed genomic or cDNA sequences. In contrast, we have devised an application of this technique that achieves amplification and cloning of the region between a single short sequence in a cDNA molecule and its unknown 3' or 5' end. We demonstrate here the utility of this strategy, termed “rapid amplification of cDNA ends” (RACE), by using it to obtain clones representing transcripts of a gene, *int-2*, expressed at low abundance in the early mouse embryo.

## METHODS

**3'-End Amplification of cDNAs.** See Fig. 1 for the scheme. *Reverse transcription.* One microgram of poly(A)<sup>+</sup> RNA (ref. 14; ref. 15, pp. 91–98) in 16.5  $\mu$ l of water was heated at 65°C for 3 min, quenched on ice, added to 2  $\mu$ l of 10 $\times$  RTC buffer (1 $\times$  RTC buffer is 50 mM Tris-HCl, pH 8.15 at 41°C/6 mM MgCl<sub>2</sub>/40 mM KCl/1 mM dithiothreitol/each dNTP at 1.5 mM), 0.25  $\mu$ l of (10 units) of RNasin (Promega Biotech, Madison, WI), 0.5  $\mu$ l of (dT)<sub>17</sub>-adaptor (1  $\mu$ g/ $\mu$ l), and 10 units of avian myeloblastosis virus reverse transcriptase (Life Sciences, Saint Petersburg, FL), and incubated for 2 hr at 41°C. The reaction mixture was diluted to 1 ml with TE (10 mM Tris-HCl, pH 7.5/1 mM EDTA) and stored at 4°C.

*Amplification.* The cDNA pool (1  $\mu$ l) and amplification (3'amp) and adaptor primers (25 pmol each) in 50  $\mu$ l of PCR cocktail [10% (vol/vol) dimethyl sulfoxide/1 $\times$  Taq polymerase buffer (New England Biolabs)/each dNTP at 1.5 mM] were denatured (5 min, 95°C) and cooled to 72°C. Then 2.5 units of *Thermus aquaticus* (Taq) DNA polymerase (Perkin-Elmer-Cetus) was added and the mixture was overlaid with 30  $\mu$ l of mineral oil (Sigma) at 72°C and annealed at 50–58°C for 2 min. The cDNA was extended at 72°C for 40 min. Using a DNA Thermal Cycler (Perkin-Elmer-Cetus), we carried out 40 cycles of amplification by using a step program (94°C, 40 sec; 50–58°C, 2 min; 72°C, 3 min), followed by a 15-min final extension at 72°C.

**5'-End Amplification of cDNAs.** See Fig. 1. One microgram of poly(A)<sup>+</sup> RNA was reverse transcribed as described above except for the addition of 20  $\mu$ l of 1 Ci (37 GBq) of [<sup>32</sup>P]dCTP and the substitution of 20 pmol of 5RT primer for (dT)<sub>17</sub>-adaptor. Excess 5RT was removed as follows: the 20- $\mu$ l cDNA pool was applied to a Bio-Gel A-5m (Bio-Rad) column (in a 2-ml serological pipette plugged with silane-treated glass wool) equilibrated with 0.05 $\times$  TE. Void volume (0.8 ml) and 30 one-drop fractions were collected. Fractions –4 to +3 relative to the first peak of radioactivity were pooled, concentrated by centrifugation under reduced pressure (Speedvac), and adjusted to 23  $\mu$ l. For tailing, 1  $\mu$ l of 6 mM dATP, 6  $\mu$ l of 5 $\times$  tailing buffer (Bethesda Research Laboratories), and 15 units of terminal deoxynucleotidyl-transferase (Bethesda Research Laboratories) were added, and the mixture was incubated for 10 min at 37°C and heated for 15 min at 65°C. The reaction mixture was diluted to 500  $\mu$ l in TE and 1- to 10- $\mu$ l aliquots were used for amplification as described for the 3'-end procedure, except for the substitution of (dT)<sub>17</sub>-adaptor (10 pmol), adaptor (25 pmol), and amplification (5'amp, 25 pmol) primers.

**Southern and RNA Blot Analysis.** Ten-microliter aliquots of RACE reaction products were separated by electrophoresis [1% agarose gel containing ethidium bromide (EtdBr) at 0.5

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Abbreviations: RACE, rapid amplification of cDNA ends; PCR, (DNA) polymerase chain reaction; 3'amp and 5'amp, gene-specific primers for 3'- and 5'-end amplification; 5RT, gene-specific primer for reverse transcription; EtdBr, ethidium bromide.



presence of the adaptor places a unique sequence at the unknown end of the cDNA. Next, a gene-specific amplification primer (3'amp) is annealed with a small portion of the first (-) strand product (generally <1 ng) and extended to generate a complementary second (+) strand. Repetitive PCR cycles using 3'amp and adaptor primers then amplify the double-stranded cDNAs. Specificity of amplification is dependent on base-pairing of 3'amp only to molecules representing the mRNA of interest. The adaptor primer is used instead of the (dT)<sub>17</sub>-adaptor primer because initial experiments suggested that long stretches of dT residues do not base pair well at the temperatures used to prevent mismatching of the specific primers.

A similar strategy is used to obtain cDNA 5' ends (Fig. 1). The initial specificity is achieved by using a gene-specific primer for reverse transcription (5RT). The primer-extended products are then separated from excess primer and a poly(A) tail is added by using dATP and terminal deoxynucleotidyl-transferase. Second (+) strand synthesis is carried out with the (dT)<sub>17</sub>-adaptor primer. Finally, the products are amplified by using the adaptor primer and a gene-specific amplification primer (5'amp) consisting of a sequence located upstream of the extension primer sequence. This "internal" primer increases the specificity and efficiency of the amplification reaction; it should bind only to the cDNAs of interest, whereas 5RT would bind to all (+) strand cDNAs present, including any generated through mismatched hybridization of 5RT during reverse transcription. Moreover, 5'amp would not bind to any residual 5RT that had been tailed. Such tailed 5RT, because of its small size and relatively large initial concentration, would serve as a potent substrate for a PCR reaction that included the 5RT and (dT)<sub>17</sub>-adaptor primers, and this would greatly decrease the efficiency of the cDNA amplification.

After amplification, the products are analyzed by restriction and Southern blot analyses and cloned. The optimal cloning strategy utilizes one restriction endonuclease that cleaves within the adaptor sequence and a second that cleaves within the amplified region. This adds selectivity to the cloning process, since most of the nonspecific cDNA products will not be cleaved by the second enzyme and thus will not be cloned. Alternatively, the RACE products can be cloned intact by also incorporating a restriction site into the 5' end of the gene-specific primer. Finally, full-length cDNA clones can be reconstructed from separate but overlapping 3' and 5' RACE products, or they can be synthesized by using primers whose sequences were obtained by analysis of the extreme 5' and 3' ends of the RACE products for PCR amplification of reverse-transcribed mRNA.

**Isolation of *int-2* cDNA Clones by Using the RACE Protocol.** We tested this scheme by generating cDNA copies of mRNA from *int-2*, a gene characterized by multiple transcripts expressed at very low abundance ( $\approx 2$  copies per cell, ref. 19), and whose complete sequence is known (20). Because we had recently isolated *int-2* cDNA clones by conventional methods (21), we had a standard against which we could judge the results of the present study. On the basis of our previous results, we expected to obtain *int-2* cDNA clones with alternative start and polyadenylation sites (Fig. 2A).

The first 3'amp primer used, 3'amp-D, was specific to the long *int-2* mRNAs (Fig. 2A). The 3'-end cDNA product of the amplification reaction was expected to be  $\approx 1050$  bp in length. DNA of the expected size was visible after EtBr staining (Fig. 2B, lane 3'D), and its identity was confirmed by Southern blot analysis using an *int-2* cDNA probe (Fig. 2C, lane 3'D). In addition, most samples contained *int-2* cDNAs of unexpected size, which were subsequently determined to be single-stranded molecules (see below). In some circumstances other reaction products were visible after EtBr staining, but they did not hybridize to the *int-2* probe; we found that such nonspecific PCR products could be mini-

mized by optimizing the annealing temperature (M.A.F., unpublished data). EtBr-staining bands were also visible in the control sample, but they did not hybridize with the *int-2* probe (Fig. 2B and C, lane 3'C).

The second 3'amp primer used, 3'amp-U, was common to both short and long classes (Fig. 2A) and thus was expected to generate cDNA products 480 and 1580 bp in length, respectively. Of these, only the 480-bp product was detectable by staining with EtBr (Fig. 2B, lane 3'U), but the presence of both cDNAs was demonstrated by Southern blot analysis (Fig. 2C, lane 3'U). The observation that the 480-bp cDNA is  $\approx 10$ -fold more abundant than the 1580-bp cDNA is inconsistent with the fact that the short classes of mRNA are only  $\approx 2$ -fold more abundant than the long ones (Fig. 2A). This finding, that the relative abundance of different cDNA products generated by multiple cycles of PCR may not accurately reflect the composition of the mRNA population, is presumably due to a decrease in PCR efficiency as extension length increases.

When *int-2* cDNA 5' ends were produced by using the RACE strategy, we expected  $\approx 690$ - and  $\approx 930$ -bp products representing the 5' ends of the class B and the less abundant class A mRNAs, respectively (Fig. 2A). Although both fragments could be detected by Southern blot analysis, they were not always visible after EtBr staining (Fig. 2B and C, lane 5'P).

The specific products of the 3' and 5'-end RACE reactions were isolated from agarose gels and cloned. The possibility afforded by the RACE protocol of separating different classes of cDNAs by gel electrophoresis prior to cloning was particularly useful in obtaining cDNAs representing class A mRNAs, which would otherwise have been difficult to detect in the presence of the much more numerous class B clones. However, we did not further size-select the RACE products in either class, and therefore we were able to examine the range of cDNAs produced by this protocol. Together the clones obtained represented all four transcripts expressed from the *int-2* gene, the longest of which is  $\approx 2.9$  kilobases (kb).

The cDNA clones representing the 3' ends of the long and short classes of *int-2* mRNA were expected to terminate at *int-2* genomic positions 7508 and 6404, respectively. Sequence analysis of four independent cDNA clones (three of the long and one of the short class) confirmed that the products obtained by the RACE method were identical to those obtained by conventional cDNA cloning methods (21). Previous studies suggested that the 5' ends of class A and B *int-2* mRNAs begin around positions 938 and 1677/1778 of the *int-2* genomic sequence, respectively (21); however, single start sites are unlikely since the *int-2* promoters lack TATA boxes, and promoters of this type usually initiate transcription at multiple sites (23-25). Sequence analysis suggested that the majority of the clones studied were full length: 11/16 class B clones and 5/9 class A clones began at or within 21 bp of the presumed start sites (Fig. 2D). A higher frequency of full-length cDNA clones presumably could have been obtained by precise size selection of the RACE products prior to cloning.

In the course of developing and testing the RACE protocol, we discovered the following:

(i) For some mRNAs (not *int-2*) not all of the 3' end cDNAs were full length. We found this to be the case when we characterized cDNA clones of transcripts from the mouse *En-1* gene (17); sequence analysis of 3'-end *En-1* cDNA clones suggested that in some cases the (dT)<sub>17</sub>-adaptor primer had bound to an A-rich region in the coding sequence (AAGAGAAGAAAAAGAA) upstream of the poly(A) tail. This could be minimized by decreasing the concentration of the (dT)<sub>17</sub>-adaptor primer to 15 ng/ $\mu$ g of mRNA (M.A.F., unpublished data).

(ii) Some of the specific reaction products appeared to be single-stranded cDNAs. These reaction products hybridized




Fig. 2. Isolation of *int-2* cDNA clones by using the RACE protocol. (A) *int-2* mRNAs in teratocarcinoma-derived endodermal cells. (Left) RNA blot hybridized with an *int-2* exon 3 probe, showing four *int-2* transcripts (21). (Right) Depiction of structures of the four classes of *int-2* transcripts found in these cells as previously defined (21). Primers used are depicted as hatched boxes with arrows. Primer sequences: 3'amp primers 3'amp-U (5'-GCGCAGAGAGAGCAGAGC-3') and 3'amp-D (5'-AGAAGGCGAGTGTCTGC-3'), complementary to (-) strand; 5RT (5'-GGCTCTGCTCTCTGC-3') and 5'amp primer (5'-CTCATGGTCCCTGTGCG-3'), complementary to (+) strand, bp, Base pairs. (B and C) Analysis of *int-2* RACE reaction products. Poly(A)<sup>+</sup> RNA isolated from endoderm-like cells obtained by treating F9 embryonal carcinoma cells with retinoic acid and dibutyl- $\alpha$ -cAMP (22) was subjected to the RACE protocol. The reaction products were analyzed by electrophoresis and EtBr staining (B) and Southern blot hybridization using an *int-2* cDNA probe (C). Marker lane (M) contains a 123-bp ladder (Bethesda Research Laboratories); sample lanes are labeled with the name of the gene-specific primer used in the amplification reaction (3'D, 3'amp-D, 3'U, 3'amp-U; 5'P, 5'amp) or as controls in which amplification was carried out in the absence of an *int-2* primer (3'C, 5'C). An + indicates single-stranded *int-2* cDNA. (D) Analysis of 5'-end *int-2* cDNA clones. The thin lines represent *int-2* genomic DNA and the open boxes the exons of the class A and B *int-2* mRNAs. The 5' ends of the mRNAs are symbolized by dotted vertical lines to indicate that multiple start sites are used. The jagged lines indicate that only the 5' portion of exon 3 is shown. The filled dots indicate the positions of the 3' ends of RACE clones as determined by sequence analysis, and the open dots the 3' ends as determined by restriction analysis.

to *int-2* probes, but they did not cleave with appropriate restriction endonucleases and were eliminated by digestion with mung bean nuclease (Fig. 3A). The quantity of these single-stranded products was also decreased by altering the buffer conditions (Fig. 3A, lane B), suggesting that complementary DNA strands are present and that appropriate binding can occur under suitable conditions. Single-stranded products are not usually observed with PCR, but use of a gene-specific primer in conjunction with a primer that binds to every cDNA present and that contains a long homopolymeric stretch may lead to greater production of one of the strands, or to mismatched pairing of some strands after the final round of PCR. Because these single-stranded products cannot easily be cloned, it is important to determine which of the specific products are double stranded.

(iii) The relative amount of longer cDNA products could be dramatically increased in several cases by substantially increasing the extension time of the initial (+) strand synthesis reaction (Fig. 3B). We also noted that small changes in the annealing temperatures (2°C) could cause significant changes in the ratio of specific to nonspecific cDNA amplification (M.A.F., unpublished data). In practice, we suggest using a conservative annealing temperature (50°C) for initial

studies and raising it until the optimal temperature is reached for obtaining the cDNA product of interest, as judged by Southern blot analysis.

## DISCUSSION

The RACE protocol described here provides an alternative to other cDNA cloning methods that is advantageous in many respects. A single gene-specific primer is used to generate 3'-end clones, whose sequences can be used, if necessary, to design the primers required for 5'-end cloning. The protocol involves few steps and the only reagents that must be specially prepared are the oligonucleotide primers. Moreover, steps common to other methods can be much simpler in the RACE protocol. For example, terminal deoxynucleotidyltransferase tailing conditions are generally optimized and monitored, since it is considered important to limit the length of the tail (4, 5). Using the RACE protocol, however, we found that the length of the poly(A) tail on the cDNA products did not exceed 34 nucleotides, even though no precautions were taken to limit tail length.

The RACE protocol is rapid and can be executed in 1 day. Moreover, it is unique in that substantial information about




Fig. 3. (A) Sensitivity of specific RACE products to mung bean nuclease. *int-2* cDNAs were generated by using the RACE 5'-end protocol and transferred into TE by spin column chromatography. The samples were then incubated at 30°C for 30 min with no additions (None), with buffer only [B: 30 mM NaOAc, pH 5.5/50 mM NaCl/1 mM ZnCl<sub>2</sub>/5% (vol/vol) glycerol], with buffer + 0.2 unit of mung bean nuclease (0.2N), or with buffer + 1 unit of mung bean nuclease (1N), and analyzed by Southern blot hybridization using an *int-2* probe. The 690-bp fragment is the amplified class B 5'-end cDNA; \* indicates single-stranded *int-2* cDNA. (B) Effect of extension time on production of specific RACE products. *int-2* cDNA was prepared by using the RACE 3'-end protocol with 3'amp-U as described in Materials and Methods, except that the time allowed for the synthesis of the (+) strand during the first cycle of PCR was varied; in subsequent steps the extension time was 3 min. Samples were analyzed by Southern blotting. Lanes are designated according to the length of the extension time (3, 10, 20, and 40 min). The 480- and 1580-bp fragments are 3'-end cDNAs of the short and long *int-2* mRNAs, respectively; \* indicates single-stranded *int-2* cDNA.

the cDNAs can be obtained prior to cloning and screening steps. Specifically, the RACE products can be examined by Southern blotting to determine whether the desired cDNAs are present and to evaluate the complexity of the cDNA population. This allows cDNAs representing unusual transcripts, such as those created by alternative splicing or by the use of alternative promoters, to be selected for cloning.

The RACE protocol is more efficient than other methods. This is evident from a comparison of the results of cloning *int-2* cDNAs by using conventional library construction vs. the RACE method. Starting with a total of 15 µg of poly(A)<sup>+</sup> RNA, we constructed two cDNA libraries, screened 2.4 × 10<sup>6</sup> recombinant phage, and isolated a total of 9 *int-2* cDNAs (21). In the present study we started with 0.5 µg of poly(A)<sup>+</sup> RNA, generated and screened several hundred recombinant plasmids with <0.05% of the RACE products, and isolated 29 independent *int-2* cDNA clones. Sequence analysis demonstrated that the 3' and 5' ends of all of four *int-2* mRNAs were accurately represented by the RACE products. Moreover, all of the 3'-end clones terminated at known polyadenylation sites and the majority of the 5'-end RACE clones appeared to be full length. Thus, we have used this technique to readily obtain full-length cDNA clones representing transcripts 1.4 to 2.9 kb long. As our data suggest, however, PCR amplification becomes less efficient with increasing fragment length. Therefore, in cases in which the generation of full-length cDNAs would require amplification over a region more than several kilobases in length, production of the desired cDNAs may be difficult. Nevertheless, in most cases it should be possible to devise strategies to overcome this limitation. Another potential problem is that a limited number of errors are introduced by the use of multiple rounds of amplification (ref. 7; ≈0.1%, unpublished data of M.A.F.). Therefore, the sequence of a cDNA clone obtained by the RACE method should be verified by comparison with sequences of several independent cDNA clones or genomic DNA.

Other potential applications of this protocol are evident. For example, primers based on amino acid sequence might be adequate for RACE cDNA cloning, although our preliminary data suggest that the feasibility of this approach may be limited by nonspecific amplification due to primer mismatch.

It should also be possible to use a modified RACE protocol to construct general cDNA libraries: one could reverse transcribe using (dT)<sub>17</sub>-adaptor primer, tail the (−) strand products with G or C residues, generate a (+) strand with a different adaptor on its 5' end, and amplify the pooled cDNAs. Since the RACE protocol as presently described requires less than 1 ng of mRNA (≈5000 copies of a low-abundance message) and this amount could be reduced considerably, it is conceivable that the construction of such general cDNA libraries ultimately could be carried out with the RNA from a single cell.

We are grateful to Monica Boyle and John Scott for technical assistance, and to our colleagues Frank Gertler, David J. Thornton, Carol Brenner, Barbara Levinson, Greg Barsh, Tom Cooper, and Tom Kornberg for helpful discussion and advice. We also thank Zena Werb for providing access to a DNA Thermal Cycler. M.A.F. and M.K.D. were supported by postdoctoral fellowships from the American Cancer Society and the Leukemia Society of America, respectively. The work was supported by Grant CD-319 from the American Cancer Society and Grant R01 HD20959 from the National Institutes of Health.

- Gubler, U. & Hoffman, B. J. (1983) *Gene* 25, 263–269.
- Heidecker, G. & Messing, J. (1987) *Methods Enzymol.* 159, 28–40.
- Efstratiadis, A., Kafatos, F. C. & Maniatis, T. (1977) *Cell* 10, 571–586.
- Okayama, H., Kawauchi, M., Brownstein, M., Lee, F., Yokota, T., & Arai, K. (1987) *Methods Enzymol.* 159, 3–27.
- Colclough, C. (1987) *Methods Enzymol.* 159, 64–83.
- Saiki, R. K., Scharf, S., Faloona, F., Mullis, K. B., Horn, G. T., Erlich, H. A. & Arnheim, N. (1985) *Science* 230, 1350–1354.
- Saiki, R. K., Gelfand, D. H., Stoffel, B., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B. & Erlich, H. A. (1988) *Science* 239, 487–491.
- Kogan, S. C., Doherty, M. & Gitschier, J. (1987) *N. Engl. J. Med.* 317, 985–990.
- Embury, S. H., Scharf, S. J., Saiki, R. K., Gholson, M. A., Golbus, M., Arnheim, N. & Erlich, H. A. (1987) *N. Engl. J. Med.* 316, 656–661.
- Lee, M. S., Chang, K., Cabanillas, F., Freireich, E. J., Trujillo, J. M., & Stass, S. A. (1987) *Science* 237, 175–178.
- Lee, C. C., Wu, X., Gibbs, R. A., Cook, R. G., Muzny, D. M., & Caskey, C. T. (1988) *Science* 239, 1288–1291.
- Ou, C.-Y., Kwok, S., Mitchell, S. W., Mack, D. H., Sninsky, J. J., Krebs, J. W., Feorillo, P., Warfield, D. & Schochetman, G. (1988) *Science* 239, 295–297.
- Powell, L. M., Wallis, S. C., Pease, R. J., Edwards, Y. H., Knott, T. J., & Scott, J. (1987) *Cell* 50, 831–840.
- Cathalia, G., Savouret, J., Mendez, B., West, B. L., Karin, M., Martial, J. A. & Baxter, J. D. (1983) *DNA* 2, 329–335.
- Maniatis, T., Fritsch, E. F. & Sambrook, J. (1982) *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Lab., Cold Spring Harbor, NY).
- Church, G. M. & Gilbert, W. (1984) *Proc. Natl. Acad. Sci. USA* 81, 1991–1995.
- Joyner, A. L., Kornberg, T., Coleman, K., Cox, D. & Martin, G. R. (1985) *Cell* 43, 29–37.
- Birnboim, C. & Doly, J. (1979) *Nucleic Acids Res.* 7, 1513–1523.
- Jakobovits, A., Shackelford, G. M., Varmus, H. E. & Martin, G. R. (1986) *Proc. Natl. Acad. Sci. USA* 83, 7806–7810.
- Moore, R., Casey, G., Brookes, S., Dixon, M., Peters, G. & Dickson, C. (1986) *EMBO J.* 5, 919–924.
- Mansour, S. B. & Martin, G. R. (1988) *EMBO J.* 7, 2035–2041.
- Strickland, S., Smith, K. K. & Marotti, K. R. (1980) *Cell* 21, 347–355.
- Melton, D. A., Konecni, D. S., Brennan, J. & Caskey, C. T. (1984) *Proc. Natl. Acad. Sci. USA* 81, 2147–2151.
- Reynolds, G. A., Baser, S. K., Osborne, T. F., Chin, D. J., Gil, G., Brown, M. S., Goldstein, J. L. & Lusky, K. L. (1984) *Cell* 38, 275–285.
- Ishii, S., Merlino, G. T. & Pastan, I. (1985) *Science* 230, 1378–1381.